Lung Cancer Dispatch
Follow
Find tag "ESMO"
3.7K views | +4 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Survey Sheds Light on Common Clinical Practice for Incompletely Resected Lung Cancer

"A landmark survey of more than 700 specialists provides crucial real-world insight into the treatments most oncologists choose for lung cancer patients whose tumour has been incompletely resected, an expert from the European Society for Medical Oncology (ESMO) says.

"Jean Yves Douillard, from the ICO Institut de Cancerologie de l'Ouest René Gauducheau, France, Chair of the ESMO Educational Committee, was commenting on a paper published in the journal Lung Cancer. In the study, researchers led by Raffaele Califano of The Christie NHS Foundation Trust, Manchester, UK, surveyed 768 oncologists from 41 European countries about the treatments they offered patients who had 'R1 resected' non-small-cell lung cancer."

Cancer Commons's insight:

Medical Xpress  |  Jun 10, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

New Drug Holds Promise for Patients with ALK Mutant NSCLC

New Drug Holds Promise for Patients with ALK Mutant NSCLC | Lung Cancer Dispatch | Scoop.it

Drug-maker Ariad Pharmaceuticals has announced promising initial results from an ongoing clinical trial investigating AP26113 in non-small cell lung cancer (NSCLC) patients. The pill demonstrates anti-tumor activity in patients who test positive for ALK mutation and may also be effective in patients with EGFR mutation. AP26113 has proven beneficial for some ALK+ patients with crizotinib resistance. These results were reported at the annual congress of the European Society for Medical Oncology (ESMO) in Vienna, Austria.

Cancer Commons's insight:

PMLiVE | Oct 2, 2012

more...
No comment yet.